Search

Your search keyword '"Armellini, E"' showing total 124 results
Start Over Author "Armellini, E"
124 results on '"Armellini, E"'

5. PC.01.8 EUS-GUIDED CHOLEDOCHODUODENOSTOMY USING A LUMENAPPOSING METAL STENT FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A RETROSPECTIVE MULTICENTER ANALYSIS

Author

Fugazza, A., primary, Fabbri, C., additional, Di Mitri, R., additional, Petrone, M.C., additional, Colombo, M., additional, Donato, G., additional, Cugia, L., additional, Amato, A., additional, Forti, E., additional, De Nucci, G., additional, Manno, M., additional, Pollino, V., additional, Binda, C., additional, Macchiarelli, R., additional, Leone, N., additional, Badas, R., additional, Lovera, M., additional, Armellini, E., additional, Redaelli, A., additional, Mangiavillano, B., additional, Brancaccio, M.L., additional, Attili, F., additional, Togliani, T., additional, Aragona, G., additional, Conte, E., additional, Maida, M., additional, Sinagra, E., additional, Repici, A., additional, Tarantino, I., additional, and Anderloni, A., additional

Published
2021
Full Text
View/download PDF

6. AF.141 EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMENAPPOSING METAL STENT FOR ACUTE CHOLECYSTITIS: RESULTS OF A MULTICENTER STUDY

Author

Binda, C., primary, Anderloni, A., additional, Forti, E., additional, Fusaroli, P., additional, Macchiarelli, R., additional, Manno, M., additional, Fugazza, A., additional, Redaelli, A., additional, Aragona, G., additional, Lovera, M., additional, Togliano, T., additional, Armellini, E., additional, Amato, A., additional, Brancaccio, M.L., additional, Badas, R., additional, Leone, N., additional, De Nucci, G., additional, Mangiavillano, B., additional, Monica, S., additional, Pollino, V., additional, Maida, M., additional, Sinagra, E., additional, Repici, A., additional, Fabbri, C., additional, and Tarantino, I., additional

Published
2021
Full Text
View/download PDF

9. Eus-Guided Choledochoduodenostomy Using a Lumen-Apposing Metal Stent for Malignant Distal Biliary Obstruction: a Retrospective Multicenter Analysis

Author

Fugazza, A, additional, Fabbri, C, additional, Di Mitri, R, additional, Petrone, MC, additional, Colombo, M, additional, Ballarè, M, additional, Cugia, L, additional, Amato, A, additional, Forti, E, additional, De Nucci, G, additional, Manno, M, additional, Pollino, V, additional, Binda, C, additional, Macchiarelli, R, additional, Leone, N, additional, Badas, R, additional, Lovera, M, additional, Armellini, E, additional, Redaelli, A, additional, Mangiavillano, B, additional, Brancaccio, ML, additional, Attili, F, additional, Togliani, T, additional, Aragona, G, additional, Conte, E, additional, Maida, M, additional, Sinagra, E, additional, Repici, A, additional, Tarantino, I, additional, and Anderloni, A, additional

Published
2021
Full Text
View/download PDF

10. EUS-Guided Gallbladder Drainage Using A Lumen-Apposing Metal Stent for Acute Cholecystitis: Results of A Multicenter Study

Author

Binda, C, additional, Anderloni, A, additional, Forti, E, additional, Fusaroli, P, additional, Macchiarelli, R, additional, Manno, M, additional, Fugazza, A, additional, Redaelli, A, additional, Aragona, G, additional, Lovera, M, additional, Togliani, T, additional, Armellini, E, additional, Amato, A, additional, Brancaccio, ML, additional, Badas, R, additional, Leone, N, additional, de Nucci, G, additional, Mangiavillano, B, additional, Sbrancia, M, additional, Pollino, V, additional, Maida, M, additional, Sinagra, E, additional, Repici, A, additional, Fabbri, C, additional, and Tarantino, I, additional

Published
2021
Full Text
View/download PDF

12. How endoscopy centers prepare to reopen after the acute COVID-19 pandemic interruption of activity

Author

Castagna, V, primary, Armellini, E, additional, Pace, F, additional, Alvisi, C, additional, Agazzi, S, additional, Amato, A, additional, Dioscoridi, L, additional, Filippi, E, additional, Gemme, C, additional, Imbesi, V, additional, Manes, G, additional, Mutignani, M, additional, Orlando, S, additional, Penagini, R, additional, Radaelli, F, additional, Reati, R, additional, Schettino, M, additional, Stradella, D, additional, Venezia, G, additional, and Verna, C, additional

Published
2021
Full Text
View/download PDF

13. Traducción al español y ensayos de campo de una nueva escala destinada a la valoración global de la gravedad de la psoriasis: el índice de psoriasis simplificado (SPI)

Author

Barquero-Orias, D.E., Armellini, E., Anderson, A.J., Armellini, A., Ortega-Loayza, A.G., Helbling, I., and Chalmers, R.J.G.

Abstract

El índice de psoriasis simplificado (SPI) fue desarrollado en el Reino Unido con el fin de proveer un resumen métrico para monitorizar los cambios en la gravedad de la psoriasis (SPI-s) y su impacto social asociado (SPI-p), junto con su comportamiento y tratamiento previo (SPI-i). Existen dos versiones complementarias, una para profesionales de salud, incluidos médicos o enfermeras (proSPI) y otra para la autoevaluación de los pacientes (saSPI). Ambas versiones han demostrado tener una variabilidad al cambio, ser confiables y tener una buena correlación con los instrumentos más utilizados en los estudios clínicos, como el PASI y el DQLI. El SPI estaba ya disponible en versiones adaptadas del francés, portugués (Brasil), holandés, arábigo y tailandés.

Published
2022
Full Text
View/download PDF

15. P.05.43 MALIGNANT TRANSFORMATION OF AN HETEROTOPIC PANCREAS DIAGNOSED BY ENDOSCOPIC ULTRASOUND GUIDED- TISSUE ACQUISITION

Author

Armellini, E., primary, Genco, C., additional, Ballarè, M., additional, Carrara, S., additional, Mazza, F., additional, Donato, G., additional, Orsello, M., additional, Saettone, S., additional, Stradella, D., additional, Tari, R., additional, Trisolini, E., additional, Occhipinti, P., additional, Battista, S., additional, and Boldorini, R., additional

Published
2019
Full Text
View/download PDF

20. OC.05.3: Endoscopic Ultrasound-Guided Tissue Sampling with a New 20G Biopsy Needle for the Characterization of Gastrointestinal Subepithelial Lesions: Results of a Preliminary Multicenter Study

Author

Antonini, F., primary, Delconte, G., additional, Fuccio, L., additional, De Nucci, G., additional, Fabbri, C., additional, Armellini, E., additional, Frazzoni, L., additional, Fornelli, A., additional, Mandelli, E., additional, Magarotto, A., additional, Occhipinti, P., additional, Masci, E., additional, Manes, G., additional, and Macarri, G., additional

Published
2017
Full Text
View/download PDF

22. AN UPDATED PROGNOSTIC MODEL FOR HCC PROGRESSION APPLICABLE TO ORGAN ALLOCATION CORRECTS THE OVERESTIMATION GENERATED BY THE CURRENT UNOS/MELD EXCEPTION

Author

De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Luca, M, Verga, G, Pinelli, D, Nani, R, Colledan, M, Fagiuoli, S, Strazzabosco, M, De Giorgio M, Vezzoli S, Cohen E, Armellini E, Luca MG, Verga G, Pinelli D, Nani R, Colledan M, Fagiuoli S, Strazzabosco M, De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Luca, M, Verga, G, Pinelli, D, Nani, R, Colledan, M, Fagiuoli, S, Strazzabosco, M, De Giorgio M, Vezzoli S, Cohen E, Armellini E, Luca MG, Verga G, Pinelli D, Nani R, Colledan M, Fagiuoli S, and Strazzabosco M

Published
2008

23. Prognostic factors affecting 1-year hepatocellular carcinoma (HCC) progression in liver transplantation candidates

Author

Luca, M, Vezzoli, S, Armellini, E, De Giorgio, M, Bezzo, R, Gaffuri, G, Nani, R, Colledan, M, Fagiuoli, S, Strazzabosco, M, Luca MG, Vezzoli S, Armellini E, De Giorgio M, Bezzo R, Gaffuri G, Nani R, Colledan M, Fagiuoli S, Strazzabosco M, Luca, M, Vezzoli, S, Armellini, E, De Giorgio, M, Bezzo, R, Gaffuri, G, Nani, R, Colledan, M, Fagiuoli, S, Strazzabosco, M, Luca MG, Vezzoli S, Armellini E, De Giorgio M, Bezzo R, Gaffuri G, Nani R, Colledan M, Fagiuoli S, and Strazzabosco M

Published
2007

31. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria

Author

De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, Strazzabosco, M, Lucà, MG, VALSECCHI, MARIA GRAZIA, ANTOLINI, LAURA, STRAZZABOSCO, MARIO, De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, Strazzabosco, M, Lucà, MG, VALSECCHI, MARIA GRAZIA, ANTOLINI, LAURA, and STRAZZABOSCO, MARIO

Abstract

Transplantation is the treatment of choice for hepatocellular carcinoma (HCC) meeting the Milan criteria. HCC and chronic liver diseases have distinct natural histories for which an equitable transplant policy must account. We enrolled and prospectively followed at a single center 206 consecutive HCC patients that presented within the Milan criteria. Patients were treated per the Barcelona Clinic Liver Cancer (BCLC) algorithm; 95% received resection, ablation, or transarterial chemoembolization. The median follow-up was 16 months. Progression occurred in 84 patients, and 8 patients died. Risk factors for the time to disease progression (death or progression beyond T2) were analyzed in 170 patients with a complete data set. Risk factors with the strongest relationship to progression included tumor diameter and tumor persistence/recurrence after local therapy (hazard ratios of 1.51 and 2.75, respectively, when transplanted patients were censored at the time of transplantation and hazard ratios of 1.53 and 3.66, respectively, when transplantation was counted as an event; P < or = 0.0001). To evaluate the current Model for End-Stage Liver Disease (MELD) exception, we compared the expected progression rate (PR) with our observed PR in 133 stage T2 patients. The current policy resulted in a large overestimation of the PR for T2 HCC and an unsatisfactory performance [Harrell's concordance index (C index) = 0.60, transplant censored; C index = 0.55, transplant as progression]. Risk factors for progression that were identified by univariate analysis were considered for multivariate analysis. With these risk factors and the patients' natural MELD scores, an adjusted model applicable to organ allocation was generated, and this decreased the discrepancy between the expected and observed PRs (C index = 0.66, transplant censored; C index = 0.69, transplant as progression). In conclusion, the current MELD exception largely overestimates progression in T2 patients treated according

Published
2010

32. HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy

Author

De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, Strazzabosco, M, Lucà, MG, Valsecchi, MG, De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, Strazzabosco, M, Lucà, MG, and Valsecchi, MG

Abstract

Background and aim. Earlier diagnosis and more effective treatments are improving the survival of patients with HCC. Moreover, the natural history of HCC patients is different from that patients with non-neoplastic indications for liver transplantation. This issue becomes critical to provide an equitable allocation policy to patients listed for transplantation. UNOS adopted a MELD-based policy that assigns the native MELD for patients with stage I HCC and 22 points for patients stage II HCC listed for Liver Transplant (LT), with an additional three points added every 3 months of waiting time in list for the latter. Organs are then assigned on the basis of the MELD score, irrespective of the indication. In countries outside the UNOS area, allocation for HCC patients still misses uniformity. Aim. The aim of the study was to generate an updated prognostic model for HCC applicable to organ allocation. Material and methods. We analysed disease progression (death or progression of HCC beyond T2 stage) in a cohort of 177 consecutive patients that presented with HCC inside the Milan criteria. Patients were treated according to the BCLC algorithm and prospectively followed by imaging every 3 months; 76 patients (43%) were listed for transplantation according to AISF/CNT guidelines. Transplanted patients were censored at the time of transplantation. Results. Median follow-up was 16 months. HCC progressed beyond T2 stage in 75 cases; 8 patients died while in T2 stage and 68 were transplanted. To verify the ability of the UNOS policy to predict HCC progression rate (PR), we compared the expected PR according to the UNOS policy with the observed PR for the respective population at risk. The current policy resulted in a large overestimation of PR in T2 patients. Two sensitivity analyses were conducted to identify risk factor (RF) for progression using the log-rank method: in the first one, transplanted patients were considered as disease progression; in the second one, only non-t

Published
2009

37. HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy

Author

De Giorgio, M., primary, Vezzoli, S., additional, Cohen, E., additional, Armellini, E., additional, Lucà, M.G., additional, Verga, G., additional, Pinelli, D., additional, Nani, R., additional, Valsecchi, M.G., additional, Antolini, L., additional, Colledan, M., additional, Fagiuoli, S., additional, and Strazzabosco, M., additional

Published
2009
Full Text
View/download PDF

42. Abdominal spilled stones: ultrasound findings.

Author

Torello Viera, F., Armellini, E., Rosa, L., Ravetta, V., Alessiani, M., Dionigi, P., and Rossi, S.

Subjects
*GALLBLADDER, *GALLSTONES, *ABDOMEN, *CHOLECYSTECTOMY, *SPLEEN, *LIVER
Abstract

Laparoscopic cholecystectomy (LC) is the treatment of choice for uncomplicated symptomatic gallstones. Spillage of stones due to gallbladder rupture has been reported in up to 33% of all LCs, but clinical sequelae caused by dropped gallstones are uncommon. We recently observed two patients with retained stones after LC. Correct diagnosis was made by abdominal ultrasonography (US) in both cases. In the first patient, who presented with fever, malaise, and weight loss 18 months after LC, abdominal US revealed hypoechoic focal lesions containing hyperechoic images with posterior shadowing of the liver and spleen. US-guided aspiration biopsies of these lesions yielded purulent material, and the injection and aspiration of saline solution provoked rolling movements of the hyperechoic images. Laparotomy confirmed the diagnosis of abscess-containing spilled gallstones. In the second patient, multiple hyperechoic images with posterior shadowing were observed in the Morison pouch during a routine US examination. The diagnosis of retained stones was consistent with the history of gallstone spillage during LC performed 2 months previously and was confirmed by computed tomographic findings of hyperdense images in the Morison pouch. The patient was asymptomatic, and treatment was thus deferred. Our experience suggests that US can be very useful in the detection of gallstones spilled during LC. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

43. [Translated article] Translation into Spanish and Field-Testing of a New Score for Evaluating Psoriasis Severity: The Simplified Psoriasis Index (SPI)

Author

Barquero-Orias, D.E., Armellini, E., Anderson, A.J., Armellini, A., Ortega-Loayza, A.G., Helbling, I., and Chalmers, R.J.G.

Abstract

The simplified psoriasis index (SPI) was developed in the United Kingdom to provide a simple summary measure for monitoring changes in psoriasis severity and associated psychosocial impact as well as for obtaining information about past disease behavior and treatment. Two complementary versions of the SPI allow for self-assessment by the patient or professional assessment by a doctor or nurse. Both versions have proven responsive to change, reliable, and interpretable, and to correlate well with assessment tools that are widely used in clinical trials—the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index. The SPI has already been translated into several languages, including French, Brazilian Portuguese, Dutch, Arabic, and Thai.

Published
2022
Full Text
View/download PDF

46. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria

Author

Massimo, De Giorgio, Stefano, Vezzoli, Eric, Cohen, Elia, Armellini, Maria Grazia, Lucà, Giulianna, Verga, Domenico, Pinelli, Roberto, Nani, Maria Grazia, Valsecchi, Laura, Antolini, Michele, Colledan, Stefano, Fagiuoli, Mario, Strazzabosco, De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, and Strazzabosco, M

Subjects
Male, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, liver transplant, organ allocation, MELD, Milan criteria, hepatocellular carcinoma, Middle Aged, Prognosis, Severity of Illness Index, Disease-Free Survival, Liver Transplantation, Cohort Studies, Treatment Outcome, MED/12 - GASTROENTEROLOGIA, Disease Progression, Humans, Female, Algorithms, Aged
Abstract

Transplantation is the treatment of choice for hepatocellular carcinoma (HCC) meeting the Milan criteria. HCC and chronic liver diseases have distinct natural histories for which an equitable transplant policy must account. We enrolled and prospectively followed at a single center 206 consecutive HCC patients that presented within the Milan criteria. Patients were treated per the Barcelona Clinic Liver Cancer (BCLC) algorithm; 95% received resection, ablation, or transarterial chemoembolization. The median follow-up was 16 months. Progression occurred in 84 patients, and 8 patients died. Risk factors for the time to disease progression (death or progression beyond T2) were analyzed in 170 patients with a complete data set. Risk factors with the strongest relationship to progression included tumor diameter and tumor persistence/recurrence after local therapy (hazard ratios of 1.51 and 2.75, respectively, when transplanted patients were censored at the time of transplantation and hazard ratios of 1.53 and 3.66, respectively, when transplantation was counted as an event; P < or = 0.0001). To evaluate the current Model for End-Stage Liver Disease (MELD) exception, we compared the expected progression rate (PR) with our observed PR in 133 stage T2 patients. The current policy resulted in a large overestimation of the PR for T2 HCC and an unsatisfactory performance [Harrell's concordance index (C index) = 0.60, transplant censored; C index = 0.55, transplant as progression]. Risk factors for progression that were identified by univariate analysis were considered for multivariate analysis. With these risk factors and the patients' natural MELD scores, an adjusted model applicable to organ allocation was generated, and this decreased the discrepancy between the expected and observed PRs (C index = 0.66, transplant censored; C index = 0.69, transplant as progression). In conclusion, the current MELD exception largely overestimates progression in T2 patients treated according to the BCLC guidelines. The tumor response to resective or ablative treatment can predict tumor progression beyond the Milan criteria, and it should be taken into account in models designed to prioritize organ allocation

Published
2010

47. HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy

Author

M. De Giorgio, S. Vezzoli, E. Cohen, E. Armellini, M.G. Lucà, G. Verga, D. Pinelli, R. Nani, M.G. Valsecchi, L. Antolini, M. Colledan, S. Fagiuoli, M. Strazzabosco, De Giorgio, M, Vezzoli, S, Cohen, E, Armellini, E, Lucà, M, Verga, G, Pinelli, D, Nani, R, Valsecchi, M, Antolini, L, Colledan, M, Fagiuoli, S, and Strazzabosco, M

Subjects
Hepatology, none, Gastroenterology
Abstract

Background and aim. Earlier diagnosis and more effective treatments are improving the survival of patients with HCC. Moreover, the natural history of HCC patients is different from that patients with non-neoplastic indications for liver transplantation. This issue becomes critical to provide an equitable allocation policy to patients listed for transplantation. UNOS adopted a MELD-based policy that assigns the native MELD for patients with stage I HCC and 22 points for patients stage II HCC listed for Liver Transplant (LT), with an additional three points added every 3 months of waiting time in list for the latter. Organs are then assigned on the basis of the MELD score, irrespective of the indication. In countries outside the UNOS area, allocation for HCC patients still misses uniformity. Aim. The aim of the study was to generate an updated prognostic model for HCC applicable to organ allocation. Material and methods. We analysed disease progression (death or progression of HCC beyond T2 stage) in a cohort of 177 consecutive patients that presented with HCC inside the Milan criteria. Patients were treated according to the BCLC algorithm and prospectively followed by imaging every 3 months; 76 patients (43%) were listed for transplantation according to AISF/CNT guidelines. Transplanted patients were censored at the time of transplantation. Results. Median follow-up was 16 months. HCC progressed beyond T2 stage in 75 cases; 8 patients died while in T2 stage and 68 were transplanted. To verify the ability of the UNOS policy to predict HCC progression rate (PR), we compared the expected PR according to the UNOS policy with the observed PR for the respective population at risk. The current policy resulted in a large overestimation of PR in T2 patients. Two sensitivity analyses were conducted to identify risk factor (RF) for progression using the log-rank method: in the first one, transplanted patients were considered as disease progression; in the second one, only non-transplanted patients were analysed. RF significant in any analysis was considered for multivariable analysis. RF with the strongest relationship to progression included tumor persistence after local therapy or recurrence inside Milan criteria (HR 2.52–3.16; p < 0.0001). Using strongest RF for progression and the patient's natural MELD, an adjusted model applicable to organ allocation was generated, which decreased the discrepancy between expected and observed PR. Conclusions. Tumor persistence/recurrence inside Milan criteria after treatment strongly predicted the risk of tumor progression beyond Milan criteria. The current MELD exception largely overestimates progression in T2 patients treated according to BCLC. An adjusted model that begins with the patient's natural MELD, and stratifies progressive risk according to the response to local treatment, better captures the PR of T2 HCC

Published
2009

48. Prognostic factors affecting 1-year hepatocellular carcinoma (HCC) progression in liver transplantation candidates

Author

Maria Grazia Lucà, R. Bezzo, Stefano Fagiuoli, Mario Strazzabosco, Roberto Nani, E. Armellini, G. Gaffuri, Stefano Vezzoli, M. De Giorgio, Michele Colledan, Luca, M, Vezzoli, S, Armellini, E, De Giorgio, M, Bezzo, R, Gaffuri, G, Nani, R, Colledan, M, Fagiuoli, S, and Strazzabosco, M

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Hepatocellular carcinoma, medicine.medical_treatment, Internal medicine, Gastroenterology, medicine, Liver transplantation, medicine.disease, business
Published
2007

49. Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) for Pancreatic Adenocarcinoma: A Review.

Author

Costanzo A, Fulco E, Marini M, Rigamonti A, Vescovi L, Floridi A, Nisi A, Pelfini E, Armellini E, and Piazzini Albani A

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest neoplasms in the world. Although various advancements in the treatment and management of this disease have been made, no significant overall survival benefit has been achieved. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been proposed as a treatment for patients who are unfit for surgery or with inoperable PDAC. We conducted a literature review of the PubMed and Embase databases to identify and analyze studies on the use of EUS-RFA in inoperable PDAC. Eleven studies with a total of 122 patients were analyzed to assess the population characteristics, feasibility and safety of the procedure, and overall survival of the population. Technical success was achieved in 95.1% of cases, and no intraoperative complications were reported. The most common early complication reported was abdominal pain (21 out of 122 patients) with a total early complication rate of 29.6%, and none of these complications affected hospital stays or post-procedure recovery. Late complications were reported in four patients (3.2%). Post-procedure cytoreduction was achieved in all patients, although disease progression was reported in 119 of 122 patients. The overall survival rate did not differ from that reported in the literature. We found that EUS-RFA could be a valid palliative option for inoperable patients, a bridge for surgery reducing the size of the tumor and its vascular relationship, or a first-line therapy in a subset of selected patients. Larger cohort and prospective studies should be conducted to establish guidelines for this procedure., Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Costanzo et al.)

Published
2024
Full Text
View/download PDF

50. The Role of Endoscopic Ultrasound and Ancillary Techniques in the Diagnosis of Autoimmune Pancreatitis: A Comprehensive Review.

Author

Metelli F, Manfredi G, Pagano N, Buscarini E, Crinò SF, and Armellini E

Abstract

Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis with a multifactorial pathogenesis. Historically, it has been classified as type 1 and type 2, according to its clinical and histological features. The diagnosis of AIP is challenging and relies on a combination of clinical, histopathologic, serologic, and imaging characteristics. In the available guidelines, the imaging hallmarks of AIP are based on cross-sectional imaging and cholangiopancreatography retrograde endoscopic findings. Endoscopic ultrasound (EUS) is generally used for pancreatic tissue acquisition to rule out pancreatic cancer and diagnose AIP with limited accuracy. Several papers reported the reliability of EUS for providing informative morphologic features of AIP. Nowadays, the improvement in the resolution of EUS conventional images and the development of new ancillary technologies have further increased the diagnostic yield of EUS: contrast-enhanced EUS and EUS elastography are non-invasive and real-time techniques that strongly support the diagnosis and management of pancreatic diseases. In this review article, we will present the role of conventional EUS and ancillary diagnostic techniques in the diagnosis of AIP to support clinicians and endosonographers in managing this condition.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results